Evidence map›Paper›PMID 35069862›Full record

ArticleExperimental and therapeutic medicine2022

Benzoyl-xanthone derivative induces apoptosis in MCF-7 cells by binding TRAF6.

Xuan Zhao, Limei Ren, Xiaoru Wang, Guangxin Han, Shuo Wang, Qingguo Yao, Yonghao Qi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Synthesis, characterization,RSC advances · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuan ZhaoDepartment of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei 050035, P.R. China.
Limei RenDepartment of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei 050035, P.R. China.
Xiaoru WangDepartment of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei 050035, P.R. China.
Guangxin HanDepartment of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei 050035, P.R. China.
Shuo WangDepartment of Pathology and Key Laboratory of Kidney of Hebei Medical University, Shijiazhuang, Hebei 050035, P.R. China.
Qingguo YaoDepartment of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei 050035, P.R. China.
Yonghao QiDepartment of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei 050035, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TNF receptor-associated factor 6 (TRAF6) has been reported to be associated with the development of cancer. Nevertheless, the exact role of TRAF6 in cancer remains unclear. The purpose of the present study was to explore the mechanism of 2-benzoyl-3-hydroxy-4-methyl-9H-xanthen-9-one leading to the inhibition of the activation of AKT and TGF-β-activated kinase 1 (TAK1), and to the apoptosis of MCF-7 cells. Using a computational docking program and examination of AKT and TAK1 level changes, a new small molecule was identified, 2-benzoyl-3-hydroxy-4-methyl-9H-xanthen-9-one, which competitively bound to TRAF6. Next, the effect of this new compound on MCF-7 cells' biological behavior was studied

Indexed as

2-benzoyl-3-hydroxy-4-methyl-9H-xanthen-9-oneAKTapoptosisMCF-7TGF-β-activated kinase 1TNF receptor-associated factor 6

Identifiers

PMID35069862
PMCPMC8764895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.